Maia Biotechnology, INC Form 4 insider transactions

MAIA Biotechnology Director Stan Smith acquired 13,740 shares of common stock through family trusts under a Rule 10b5-1 plan.

MAIA Biotechnology's CEO, Vlad Vitoc, filed an amended Form 4 to correct the reported share balance beneficially owned by his spouse.

MAIA Biotechnology's CEO, Vlad Vitoc, filed an amended Form 4 to correct previously reported direct and indirect beneficial ownership of common stock.

MAIA Biotechnology's CEO, Vlad Vitoc, has significantly increased his direct ownership in the company through two recent open market purchases.

MAIA Biotechnology Director Cristian Luput acquired additional common stock through two separate transactions in late November 2025.

MAIA Biotechnology Director Stan Smith acquired 15,000 shares of common stock, increasing his indirect beneficial ownership.

MAIA Biotechnology Director Cristian Luput purchased 10,000 shares of common stock at $0.9785 per share, increasing his beneficial ownership.

MAIA Biotechnology's CEO, Vlad Vitoc, increased his direct ownership by acquiring 10,500 shares of common stock at an average price of $0.9661.

MAIA Biotechnology Director Stan Smith acquired 25,000 shares of common stock across two transactions in late November 2025, increasing his indirect beneficial ownership.

MAIA Biotechnology's CEO, Vlad Vitoc, increased his direct ownership in the company by purchasing 11,800 shares of common stock in late November 2025.

MAIA Biotechnology Director Stan Smith acquired 24,844 stock options at an exercise price of $1.80, vesting immediately.

MAIA Biotechnology Director Jean-Manasse Theagene acquired 20,459 stock options at an exercise price of $1.8, vesting immediately.

MAIA Biotechnology Director Cristian Luput acquired 21,434 stock options at an exercise price of $1.80, vesting immediately.

MAIA Biotechnology Director Louie Ngar Yee was granted 25,331 stock options at an exercise price of $1.80, vesting immediately.

MAIA Biotechnology Director Ramiro Guerrero was granted 20,459 stock options exercisable at $1.80 per share, vesting immediately.

MAIA Biotechnology Director Steven M. Chaouki received a grant of 20,946 stock options exercisable at $1.80 per share.

MAIA Biotechnology Director Stan Smith acquired 19,230 shares of common stock and 19,230 warrants through a trust.

MAIA Biotechnology, Inc. Director Stan Smith was granted 24,747 stock options with an exercise price of $1.8 per share, vesting immediately.

Ramiro Guerrero, a Director at MAIA Biotechnology, Inc., has acquired 20,380 stock options with an exercise price of $1.80, vesting immediately.

MAIA Biotechnology, Inc. Director Steven M. Chaouki acquired 20,865 stock options with an exercise price of $1.80 per share, vesting immediately.

MAIA Biotechnology, Inc. Director Ngar Yee Louie was granted 25,232 stock options with an exercise price of $1.80 per share, vesting immediately on June 30, 2025.

MAIA Biotechnology, Inc. Director Cristian Luput was granted 21,350 stock options with an exercise price of $1.80 per share, vesting immediately.

MAIA Biotechnology, Inc. Director Jean-Manasse Theagene was granted 20,380 stock options exercisable at $1.80 per share, vesting immediately.

MAIA Biotechnology, Inc. Director and 10% owner Stan Smith has increased his beneficial ownership by acquiring 33,333 shares of common stock and 33,333 warrants through a Securities Purchase Agreement.

Vlad Vitoc, CEO of MAIA Biotechnology, reports the acquisition of 400,000 stock options.

Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, Inc., was granted stock options for 200,000 shares on May 14, 2025.

Jeffrey Himmelreich, Head of Finance at MAIA Biotechnology, Inc., reports the acquisition of stock options.

Director Ramiro Guerrero purchased 20,000 shares of MAIA Biotechnology and related warrants on May 8, 2025, at a price of $1.50 per share and $2.05 per warrant.

Director Stan Smith reports purchasing MAIA Biotechnology common stock and warrants, increasing his indirect beneficial ownership.

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology, Inc.